1. Markowitz M, Morales-Ramirez JO, Nguyen BY, Kovacs CM, Steigbigel RT, Cooper DA, Liporace R, Schwartz R, Isaacs R, Gilde LR, Wenning L, Zhao J, Teppler H (2006) Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 43(5):509–515
2. Grinsztejn B, Nguyen BY, Katlama C, Gatell J, Lazzarin A, Vittecoq D, Gonzalez C, Chen J, Isaacs R, Team Tps (2006) Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. In: 13th conference on retroviruses and opportunistic infections (CROI), Denver, USA, 5–8 February 2006. p Abstract 159LB
3. Cooper D, Gatell J, Rockstroh J, Katlama C, Yeni P, Lazzarin A, Chen J, Isaacs R, Teppler H, Nguyen B, Group B-S (2007) Results of BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. In: 14th conference on retroviruses and opportunistic infections (CROI), Los Angeles, CA, USA, 25–28 February 2007. p Abstract 105aLB
4. Steigbigel R, Kumar P, Eron J, Schechter M, Markowitz M, Loufty M, Zhao J, Isaacs R, Nguyen BY, Teppler H, Group tB-S (2007) Results of BENCHMRK-2, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. In: 14th conference on retroviruses and opportunistic infections (CROI), Los Angeles, CA, USA, 25–28 February 2007. p Abstract 105bLB
5. Zolopa AR, Berger DS, Lampiris H, Zhong L, Chuck SL, Enejosa JV, Kearney BP, Cheng AK (2010) Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis 201(6):814–822. doi: 10.1086/650698